Molecular Insights into BZW1 Expression and [¹⁸F]FDG PET/CT Metabolic Parameters in LUAD.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI:10.1007/s11307-025-02063-8

Jiahe Li, Siqi Wang, Guangfang Chen, Yiyi Hu, Hongliang Wang, Hua Wei, Haiyan Liu, Caozhe Cui, Yayuan Li, Xiaomeng Li, Xinchao Wang, Jianbo Cao, Zhifang Wu

{"title":"Molecular Insights into BZW1 Expression and [18F]FDG PET/CT Metabolic Parameters in LUAD.","authors":"Jiahe Li, Siqi Wang, Guangfang Chen, Yiyi Hu, Hongliang Wang, Hua Wei, Haiyan Liu, Caozhe Cui, Yayuan Li, Xiaomeng Li, Xinchao Wang, Jianbo Cao, Zhifang Wu","doi":"10.1007/s11307-025-02063-8","DOIUrl":null,"url":null,"abstract":"Purpose: Early detection and intervention in lung adenocarcinoma (LUAD) are critical for improving patient prognosis. This study explores the role of basic leucine zipper and W2 domains 1 (BZW1, BZAP45) in regulating malignant cellular behavior and glycolytic metabolism in LUAD.Procedures: Bioinformatics and clinical information analysis was conducted to study BZW1 expression and its relationship with prognosis, glycolysis-related genes expression and PET/CT parameters of 2-deoxy-2-[1⁸F]fluoro-D-glucose ([18F]FDG) in LUAD. BZW1 was knocked out in A549 cell line and verified. In vitro and in vivo studies were performed to analyze BZW1's impact on malignant behaviors and glycolysis. Non-targeted mass spectrometry analyzed xenograft tumor metabolites and potential biomarkers.Results: Bioinformatic analyses identified BZW1 as a pivotal gene driving LUAD progression. The retrospective analysis revealed that BZW1 expression is elevated in LUAD tissues and is significantly correlated with clinical tumor parameters and metabolic parameters obtained from [18F]FDG PET/CT. In vitro assays demonstrated that BZW1 overexpression promotes LUAD cell proliferation, migration, and invasion. In vivo experiments with mouse xenograft models confirmed that BZW1 promotes tumor growth. Further analysis revealed that BZW1 may facilitate glycolysis and the Warburg effect by upregulating hypoxia inducible factor-1α (HIF-1α) and cellular Myelocytomatosis (c-Myc).Conclusions: These findings highlighted the role of BZW1 in LUAD metabolism and may promote tumor progression through modulating of glycolytic pathways. In conclusion, BZW1 is significantly associated with LUAD malignancy and [18F]FDG PET/CT derived metabolic parameters. It could provide a potential molecular target for the diagnosis and treatment of LUAD, offering new insights into precision oncology.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"142-154"},"PeriodicalIF":2.5000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-02063-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Early detection and intervention in lung adenocarcinoma (LUAD) are critical for improving patient prognosis. This study explores the role of basic leucine zipper and W2 domains 1 (BZW1, BZAP45) in regulating malignant cellular behavior and glycolytic metabolism in LUAD.

Procedures: Bioinformatics and clinical information analysis was conducted to study BZW1 expression and its relationship with prognosis, glycolysis-related genes expression and PET/CT parameters of 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) in LUAD. BZW1 was knocked out in A549 cell line and verified. In vitro and in vivo studies were performed to analyze BZW1's impact on malignant behaviors and glycolysis. Non-targeted mass spectrometry analyzed xenograft tumor metabolites and potential biomarkers.

Results: Bioinformatic analyses identified BZW1 as a pivotal gene driving LUAD progression. The retrospective analysis revealed that BZW1 expression is elevated in LUAD tissues and is significantly correlated with clinical tumor parameters and metabolic parameters obtained from [¹⁸F]FDG PET/CT. In vitro assays demonstrated that BZW1 overexpression promotes LUAD cell proliferation, migration, and invasion. In vivo experiments with mouse xenograft models confirmed that BZW1 promotes tumor growth. Further analysis revealed that BZW1 may facilitate glycolysis and the Warburg effect by upregulating hypoxia inducible factor-1α (HIF-1α) and cellular Myelocytomatosis (c-Myc).

Conclusions: These findings highlighted the role of BZW1 in LUAD metabolism and may promote tumor progression through modulating of glycolytic pathways. In conclusion, BZW1 is significantly associated with LUAD malignancy and [¹⁸F]FDG PET/CT derived metabolic parameters. It could provide a potential molecular target for the diagnosis and treatment of LUAD, offering new insights into precision oncology.

查看原文本刊更多论文

LUAD中BZW1表达及[18F]FDG PET/CT代谢参数的分子研究

目的：肺腺癌（LUAD）的早期发现和干预对改善患者预后至关重要。本研究探讨碱性亮氨酸拉链和W2结构域1 （BZW1, BZAP45）在LUAD中调节恶性细胞行为和糖酵解代谢中的作用。方法：采用生物信息学和临床信息分析方法，研究LUAD患者2-脱氧-2-[1⁸F]氟-d -葡萄糖（[18F]FDG） BZW1表达及其与预后、糖酵解相关基因表达及PET/CT参数的关系。BZW1在A549细胞系中被敲除并验证。体外和体内研究分析BZW1对恶性行为和糖酵解的影响。非靶向质谱分析异种移植物肿瘤代谢物和潜在的生物标志物。结果：生物信息学分析发现BZW1是驱动LUAD进展的关键基因。回顾性分析发现，BZW1在LUAD组织中表达升高，并与[18F]FDG PET/CT获得的临床肿瘤参数和代谢参数显著相关。体外实验表明，BZW1过表达可促进LUAD细胞增殖、迁移和侵袭。小鼠异种移植模型的体内实验证实BZW1促进肿瘤生长。进一步分析发现，BZW1可能通过上调缺氧诱导因子-1α (HIF-1α)和细胞髓细胞瘤病（c-Myc），促进糖酵解和Warburg效应。结论：这些发现强调了BZW1在LUAD代谢中的作用，并可能通过调节糖酵解途径促进肿瘤进展。综上所述，BZW1与LUAD恶性和[18F]FDG PET/CT衍生代谢参数显著相关。它可能为LUAD的诊断和治疗提供潜在的分子靶点，为精准肿瘤学提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.